Unknown

Dataset Information

0

Exploring SPK98 for the Selective Sensitization of ATM- or P53-Deficient Cancer Cells.


ABSTRACT: Frequent mutation in the ATM/P53 signaling pathway has been documented in many human cancers. Reportedly, cancer cells with deficient P53/ATM pathways depend on functional Ataxia-telangiectasia and Rad3-related (ATR) protein for survival. This has prompted research in developing ATR inhibitors for the selective sensitization of cancer cells that are P53/ATM-deficient, but no clinical success has been attained thus far. This study explores the therapeutic potential of SPK98, an analogue of Torin2 in P53- and ATM-deficient cancer cells. Furthermore, the prospect of improving the therapeutic outcome of the genotoxic agent was also explored. SPK98 was shown to inhibit full-length human ATR protein purified from HEK293T cells. Cellular investigation using SPK98 demonstrated that it selectively sensitizes P53- and ATM-deficient cells at low concentrations compared to P53-/ATM-proficient cells. Furthermore, SPK98 drives the cancer cells toward cell death by promoting the formation of DNA double-strand breaks. Taken together, our findings suggest that SPK98 is a promising therapeutic molecule for P53- or ATM-deficient malignancy that merits additional preclinical investigation.

SUBMITTER: Priya B 

PROVIDER: S-EPMC9909806 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Exploring SPK98 for the Selective Sensitization of ATM- or P53-Deficient Cancer Cells.

Priya Bhanu B   Dubey Gurudutt G   Kirubakaran Sivapriya S  

ACS omega 20230130 5


Frequent mutation in the ATM/P53 signaling pathway has been documented in many human cancers. Reportedly, cancer cells with deficient P53/ATM pathways depend on functional Ataxia-telangiectasia and Rad3-related (ATR) protein for survival. This has prompted research in developing ATR inhibitors for the selective sensitization of cancer cells that are P53/ATM-deficient, but no clinical success has been attained thus far. This study explores the therapeutic potential of SPK98, an analogue of Torin2  ...[more]

Similar Datasets

| S-EPMC3443949 | biostudies-literature
| S-EPMC5462076 | biostudies-literature
| S-EPMC8275734 | biostudies-literature
| S-EPMC3527202 | biostudies-literature
| S-EPMC3235156 | biostudies-literature
| S-EPMC4359966 | biostudies-literature
| S-EPMC2742175 | biostudies-literature
| S-EPMC5523659 | biostudies-literature
| S-EPMC9815235 | biostudies-literature
| S-EPMC8484348 | biostudies-literature